Dynavax to Be Acquired by Sanofi for $2.2 Billion
Cooley advised Dynavax Technologies, a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B), a shingles vaccine candidate and a differentiated clinical-stage pipeline, on its definitive agreement to be acquired by Sanofi for $15.50 per share in cash, representing an equity value of $2.2 billion. The acquisition […]
Qualified to Be Acquired by Salesforce
Cooley advised Qualified, a leading provider of agentic artificial intelligence marketing solutions, on its definitive agreement to be acquired by Salesforce. Qualified to Be Acquired by Salesforce
Confluent to Be Acquired by IBM
Cooley advised Confluent, the data streaming pioneer, on its definitive agreement under which IBM will acquire all of the issued and outstanding common shares of Confluent for $31 per share, representing an enterprise value of approximately $11 billion. IBM and Confluent will enable end-to-end integration of applications, analytics, data systems […]
Cidara Therapeutics to Be Acquired by Merck
Cooley advised Cidara Therapeutics, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, on its definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion. The transaction is expected to close in the first quarter […]
Cooley Advises PrizePicks on Sale to Allwyn for up to $4.15 Billion
Cooley advised PrizePicks, the largest daily fantasy sports operator in North America, on its definitive agreement for Allwyn International to acquire a majority stake in PrizePicks at an upfront enterprise value of $2.5 billion. If PrizePicks achieves certain performance metrics over the next three years, additional cash consideration under the […]
Cooley Advises Investor Syndicate on $2.25 Billion Acquisition of HistoSonics
Cooley advised a syndicate of globally recognized private and public investors in connection with the management-led majority stake acquisition of HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, valuing the company at approximately $2.25 billion. The investors include K5 Global, Bezos Expeditions and Wellington Management; […]
Vicebio to Be Acquired by Sanofi for $1.6 Billion
Cooley advised Medicxi and other venture capital investors in Sanofi’s $1.6 billion acquisition of Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections. Vicebio shareholders will receive up to a total of $1.6 billion, including an upfront payment of $1.15 billion and development and regulatory milestones payments […]
Play AI Acquired by Meta
Cooley advised Play AI, a startup that uses artificial intelligence (AI) to generate human-sounding voices, on its acquisition by Meta. Play AI Acquired by Meta
Capstan Therapeutics Announces up to $2.1 Billion Acquisition by AbbVie
Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie. AbbVie will acquire Capstan, including CPTX2309 a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 chimeric antigen […]
SiteOne Therapeutics to Be Acquired by Eli Lilly for up to $1 Billion
Cooley advised SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, on its acquisition by Eli Lilly. Under the terms of the agreement, Eli Lilly will acquire SiteOne, and SiteOne shareholders could receive up to $1 billion in […]